Limitations of the NMN-BBB score in capturing therapeutic accessibility
The Lancet Medical Imaging & Theranostics · 2026
DOI: 10.1016/j.lanmit.2026.100011 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Ali Nabavizadeh und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We read with interest the Personal View by Nathalie L Albert and colleagues proposing the Nuclear Medicine and Neuro-Oncology blood–brain barrier (NMN-BBB) score for imaging-based classification of BBB disruption in glioblastoma.1 The authors should be commended for highlighting the importance of heterogeneous BBB permeability in neuro-oncology trials and for proposing a pragmatic imaging-based framework for patient stratification. However, several conceptual and methodological limitations warrant discussion.
Zitieren
APA
Nabavizadeh, A., Barajas, R. F., Johnson, D. R., & Ivanidze, J. (2026). Limitations of the NMN-BBB score in capturing therapeutic accessibility. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100011
Vancouver
Nabavizadeh A, Barajas RF, Johnson DR, Ivanidze J. Limitations of the NMN-BBB score in capturing therapeutic accessibility. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100011
BibTeX
@article{Nabavizadeh2026,
author = {Nabavizadeh, Ali and Barajas, Ramon F and Johnson, Derek R and Ivanidze, Jana},
title = {Limitations of the NMN-BBB score in capturing therapeutic accessibility},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
doi = {10.1016/j.lanmit.2026.100011}
}
EUVIMED